Skip to content

A proof of concept study with NVD-003, an autologous osteogenic bone graft, in the treatment of congenital pseudarthrosis of the tibia in pediatric patients.

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-515478-29-00
Acronym
NVD003-CLN02
Enrollment
2
Registered
2024-07-02
Start date
2022-11-28
Completion date
Unknown
Last updated
2025-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital pseudarthrosis of the tibia

Brief summary

Short term safety focusses on ATC and NVD 003 related (S)AEs between screening and 3 months post-GS (V6 included), Mid long-term safety focusses on the NVD 003 graft implantation, NVD 003 related (S)AEs and the surgical reintervention rate, including all corrective surgeries following a confirmed failure of the index surgery, captured between 3 months (V6 excluded) and 12 months post-GS (V8 included), Long-term safety evaluates the NVD 003 related SAEs between 12 months post-GS (V8 excluded) and 24 months (V9 included)

Detailed description

Based on CT-scan • Centrally analyze the tibial length difference at GS and 12 months post-GS • Centrally analyze the bone formation at 3-, 6-, and 12-months post GS • Centrally analyze bone union and remodeling at 12 months post-GS, Based on X-ray: • Centrally analyze the positioning of the graft at 6 weeks and 24 months post-GS • Centrally analyze the alignment of the concerned bones and fixation devices at 6 weeks and 24 months post-GS • Centrally evaluate bone growth based on tibial length evolution and leg length differences between both legs at 6 weeks and 24 months post-GS, Assess the clinical evolution of the patient, before and after the grafting surgery, by means of the investigator assessed “Clinical Global Impression”, Severity Scale (CGI-S) and Improvement Scale (CGI-I) at screening, at hospital discharge, 6 weeks, 3-, 6-, 12-, and 24-months post-grafting. a. CGI-S b. CGI-I:, a. CGI-S i. Screening: general functioning, walking ability, weight bearing, presence of pain and pain at palpation, appearance of the leg, social activities (including school attendance and sports activities)., b. CGI-I: i. Hospital discharge and 6 weeks post-GS: general functioning, presence of pain and pain at palpation, appearance of the leg ii. 3 months-24 months post-GS: general functioning, walking ability, weight bearing, presence of pain and pain at palpation, appearance of the leg, social activities (including school attendance and sports activities).

Interventions

DRUGNVD-003

Sponsors

Novadip Biosciences
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
0 Years to 17 Years

Design outcomes

Primary

MeasureTime frame
Short term safety focusses on ATC and NVD 003 related (S)AEs between screening and 3 months post-GS (V6 included), Mid long-term safety focusses on the NVD 003 graft implantation, NVD 003 related (S)AEs and the surgical reintervention rate, including all corrective surgeries following a confirmed failure of the index surgery, captured between 3 months (V6 excluded) and 12 months post-GS (V8 included), Long-term safety evaluates the NVD 003 related SAEs between 12 months post-GS (V8 excluded) and 24 months (V9 included)

Secondary

MeasureTime frame
Based on CT-scan • Centrally analyze the tibial length difference at GS and 12 months post-GS • Centrally analyze the bone formation at 3-, 6-, and 12-months post GS • Centrally analyze bone union and remodeling at 12 months post-GS, Based on X-ray: • Centrally analyze the positioning of the graft at 6 weeks and 24 months post-GS • Centrally analyze the alignment of the concerned bones and fixation devices at 6 weeks and 24 months post-GS • Centrally evaluate bone growth based on tibial length evolution and leg length differences between both legs at 6 weeks and 24 months post-GS, Assess the clinical evolution of the patient, before and after the grafting surgery, by means of the investigator assessed “Clinical Global Impression”, Severity Scale (CGI-S) and Improvement Scale (CGI-I) at screening, at hospital discharge, 6 weeks, 3-, 6-, 12-, and 24-months post-grafting. a. CGI-S b. CGI-I:, a. CGI-S i. Screening: general functioning, walking ability, weight bearing, presence of pain an

Countries

Belgium

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026